Tempest Therapeutics Gross Profit

The latest gross profit for TPST is $-22M as of June 2026. That compares with $180K in the prior-year period — down 12702.3% year over year. That is below the Healthcare sector average of $65B. Investors often review this figure alongside Tempest Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, TPST's gross profit moved from $180K to $-22M — a 12702.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Tempest Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, TPST currently prints $-22M for gross profit, while the sector average sits near $65B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Tempest Therapeutics's growth, margins, and balance sheet.

A gross profit figure of $-22M for TPST is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $65B. Explore the charts below for those layers of context.

After noting TPST's gross profit ($-22M), review year-over-year change from $180K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.